S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
Log in

NASDAQ:CFRXContraFect Stock Price, Forecast & News

$5.33
-0.05 (-0.93 %)
(As of 08/12/2020 02:02 PM ET)
Add
Compare
Today's Range
$5.28
Now: $5.33
$5.50
50-Day Range
$5.51
MA: $6.33
$7.81
52-Week Range
$2.69
Now: $5.33
$13.40
Volume11,996 shs
Average Volume271,787 shs
Market Capitalization$81.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.01
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Read More
ContraFect logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.57 per share
Book Value$1.01 per share

Profitability

Net Income$-12,790,000.00

Miscellaneous

Employees20
Market Cap$81.71 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable
$5.33
-0.05 (-0.93 %)
(As of 08/12/2020 02:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ContraFect (NASDAQ:CFRX) Frequently Asked Questions

How has ContraFect's stock been impacted by COVID-19 (Coronavirus)?

ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CFRX stock has decreased by 23.4% and is now trading at $5.33.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ContraFect?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ContraFect
.

When is ContraFect's next earnings date?

ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for ContraFect
.

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $0.10.
View ContraFect's earnings history
.

When did ContraFect's stock split? How did ContraFect's stock split work?

ContraFect's stock reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CFRX?

4 brokers have issued 1 year price targets for ContraFect's stock. Their forecasts range from $12.00 to $22.00. On average, they anticipate ContraFect's share price to reach $16.00 in the next year. This suggests a possible upside of 200.2% from the stock's current price.
View analysts' price targets for ContraFect
.

Has ContraFect been receiving favorable news coverage?

Media coverage about CFRX stock has trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ContraFect earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about ContraFect
.

Are investors shorting ContraFect?

ContraFect saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 167,000 shares, a decline of 49.1% from the January 31st total of 328,100 shares. Based on an average daily volume of 244,500 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.7% of the company's shares are sold short.
View ContraFect's Short Interest
.

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Matinas BioPharma (MTNB), Novavax (NVAX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Vaxart (VXRT) and Dynavax Technologies (DVAX).

Who are ContraFect's key executives?

ContraFect's management team includes the following people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
  • Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different institutional and retail investors. Top institutional shareholders include Minot Wealth Management LLC (0.58%), New York State Common Retirement Fund (0.09%) and UBS Group AG (0.03%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger.
View institutional ownership trends for ContraFect
.

Which major investors are buying ContraFect stock?

CFRX stock was bought by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC, New York State Common Retirement Fund, and UBS Group AG. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff, and Michael Messinger.
View insider buying and selling activity for ContraFect
.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $5.33.

How big of a company is ContraFect?

ContraFect has a market capitalization of $81.71 million. The biotechnology company earns $-12,790,000.00 in net income (profit) each year or $1.11 on an earnings per share basis. ContraFect employs 20 workers across the globe.

What is ContraFect's official website?

The official website for ContraFect is www.contrafect.com.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.